Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Aspire Biopharma Holdings, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide disclosure under this Item 3. Item